QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
QQQ   328.11 (+0.83%)
AAPL   142.92 (+2.77%)
MSFT   229.53 (+1.58%)
FB   278.01 (+1.28%)
GOOGL   1,894.28 (+0.09%)
AMZN   3,294.00 (+0.05%)
TSLA   880.80 (+4.03%)
NVDA   546.13 (-0.43%)
BABA   261.38 (+1.07%)
CGC   32.91 (-2.63%)
GE   10.99 (-1.08%)
MU   81.28 (-1.22%)
AMD   94.13 (+1.44%)
NIO   59.99 (-3.16%)
T   29.11 (+0.62%)
F   11.29 (-2.00%)
ACB   10.16 (-4.60%)
BA   203.36 (-1.20%)
DIS   171.89 (-0.52%)
NFLX   556.78 (-1.48%)
GILD   68.16 (+1.82%)
Log in
NASDAQ:AZN

AstraZeneca Stock Forecast, Price & News

$54.01
+0.76 (+1.43 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.59
Now: $54.01
$54.21
50-Day Range
$48.52
MA: $50.26
$53.25
52-Week Range
$36.15
Now: $54.01
$64.94
Volume12.77 million shs
Average Volume12.70 million shs
Market Capitalization$141.75 billion
P/E Ratio56.26
Dividend Yield1.65%
Beta0.55
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); and Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

27th out of 1,922 stocks

Pharmaceutical Preparations Industry

11th out of 771 stocks

Analyst Opinion: 4.3Community Rank: 2.1Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AZN
CUSIPN/A
CIKN/A
Phone44 20 3749 5000
Employees70,600
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$24.38 billion
Cash Flow$3.33 per share
Book Value$5.56 per share

Profitability

Net Income$1.34 billion

Miscellaneous

Outstanding Shares2,624,593,000
Market Cap$141.75 billion
Next Earnings Date2/11/2021 (Confirmed)
OptionableOptionable
$54.01
+0.76 (+1.43 %)
(As of 01/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AstraZeneca (NASDAQ:AZN) Frequently Asked Questions

How has AstraZeneca's stock price been impacted by Coronavirus?

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 21.2% and is now trading at $54.01.
View which stocks have been most impacted by COVID-19
.

Is AstraZeneca a buy right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 2 sell ratings, 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AstraZeneca stock.
View analyst ratings for AstraZeneca
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AstraZeneca?

Wall Street analysts have given AstraZeneca a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstraZeneca wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

1,263 employees have rated AstraZeneca CEO Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among AstraZeneca's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

When is AstraZeneca's next earnings date?

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for AstraZeneca
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) issued its earnings results on Thursday, November, 5th. The company reported $0.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by $0.02. The company earned $6.58 billion during the quarter, compared to analysts' expectations of $6.54 billion. AstraZeneca had a trailing twelve-month return on equity of 37.23% and a net margin of 9.65%.
View AstraZeneca's earnings history
.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca declared a semi-annual dividend on Friday, July 31st. Stockholders of record on Friday, August 14th will be given a dividend of $0.45 per share on Monday, September 14th. This represents a yield of 2.5%. The ex-dividend date is Thursday, August 13th.
View AstraZeneca's dividend history
.

Is AstraZeneca a good dividend stock?

AstraZeneca pays an annual dividend of $0.88 per share and currently has a dividend yield of 1.65%. The dividend payout ratio of AstraZeneca is 50.29%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 33.85% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.
View AstraZeneca's dividend history.

When did AstraZeneca's stock split? How did AstraZeneca's stock split work?

AstraZeneca's stock split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly created shares were payable to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

What price target have analysts set for AZN?

14 analysts have issued twelve-month target prices for AstraZeneca's stock. Their forecasts range from $60.00 to $175.00. On average, they anticipate AstraZeneca's stock price to reach $90.00 in the next twelve months. This suggests a possible upside of 66.6% from the stock's current price.
View analysts' price targets for AstraZeneca
or view Wall Street analyst' top-rated stocks.

Who are some of AstraZeneca's key competitors?

What other stocks do shareholders of AstraZeneca own?

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 61)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 68)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 49)
  • Prof. Ralph Knöll, Chief Scientist
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer
  • Ms. Fiona Cicconi, Exec. VP of HR
  • Dr. Menelas Pangalos, Exec. Vice-Pres of BioPharmaceuticals R&D
  • Dr. Ruud Dobber, Exec. Vice-Pres of BioPharmaceuticals Bus. Unit

What is AstraZeneca's stock symbol?

AstraZeneca trades on the NASDAQ under the ticker symbol "AZN."

Who are AstraZeneca's major shareholders?

AstraZeneca's stock is owned by many different retail and institutional investors. Top institutional investors include KAMES CAPITAL plc (0.02%), Vigilant Capital Management LLC (0.01%), Park National Corp OH (0.01%), Janney Montgomery Scott LLC (0.01%), Candriam Luxembourg S.C.A. (0.01%) and FNY Investment Advisers LLC (0.01%).
View institutional ownership trends for AstraZeneca
.

Which institutional investors are selling AstraZeneca stock?

AZN stock was sold by a variety of institutional investors in the last quarter, including Avantax Advisory Services Inc., Janney Montgomery Scott LLC, Crossmark Global Holdings Inc., Pacer Advisors Inc., Raymond James Trust N.A., Ritholtz Wealth Management, TIAA FSB, and Fulton Breakefield Broenniman LLC.
View insider buying and selling activity for AstraZeneca
or view top insider-selling stocks.

Which institutional investors are buying AstraZeneca stock?

AZN stock was acquired by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, FNY Investment Advisers LLC, Candriam Luxembourg S.C.A., Guild Investment Management Inc., Kestra Advisory Services LLC, New England Research & Management Inc., Diversified Trust Co, and Vigilant Capital Management LLC.
View insider buying and selling activity for AstraZeneca
or or view top insider-buying stocks.

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $54.01.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of $141.75 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44 20 3749 5000 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.